29 January 2019The ManagerCompany Announcements OfficeASX Limited, 20 Bridge StSYDNEY NSW 2000Dear SirAPPENDIX 4CInvion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 31 December 2018.The Company held cash reserves of $0.642 million at the end of December, with net operating cashoutflows during the quarter of $1.004 million, consistent with forecasts.In accordance with strategy, activity in coming quarters will be directed to the clinical development ofthe Photosoft™ technology, the fully burdened costs of which are funded non-dilutively on a quarterlybasis via Invion’s R&D services agreement with The Cho Group, a Hong Kong based group that fundsand has successfully commercialised a number of unique and advanced technologies.Subsequent to the end of the quarter, the company received R&D services funding from The ChoGroup for activities undertaken in the December quarter.
IVX Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
